Company Overview
Company Type: Public Company
Website: www.appilitherapeutics.com
Number of Employees: 9
Ticker: APLI (TSX)
Year Founded: 2015


Business Description
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.3
Market Capitalization
6.1
TEV/Total Revenue
39.6x
EBITDA
(8.1)
Total Enterprise Value
13.2
TEV/EBITDA
NM
EBIT
(8.1)
Cash & ST Invst.
0.5
P/Diluted EPS Before Extra
NM
Net Income
(8.5)
Total Debt
7.7
Price/Tang BV
NM
Capital Expenditure
0.0
Total Assets
2.2
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Mar-31-2024 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
Revenue (mm)
0.00
0.00
0.00
0.00
0.00



Non-Periodic Estimates

Recommendation
Hold (3.00)
Target Price
0.23
Potential Upside
400.00%


Key Professionals
Name
Title
Cilla, Donald D.
CEO, President & Director
Howling, Kenneth G.
Chief Financial Officer
Nabors, Gary S.
Chief Development Officer

Key Board Members
Name
Title
Balboni, Armand 
Chairman of the Board
Cilla, Donald D.
CEO, President & Director
Matkovits, Theresa 
Lead Independent Director
Stenzler, Rochelle E.
Independent Director
Bloom, Brian Matthew
Director
Froehlich, Juergen 
Independent Director
Marusic, Lidija 
Board Observer
Narayan, Sridhar 
Member of Scientific Advisory Board
Shinabarger, Dean L.
Member of Advisory Board
Silver, Lynn L.
Member of Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
#21-1344 Summer Street | Halifax, NS | B3H 0A8 | Canada
Phone: 902-442-4655    

Current and Pending Investors
Atlantic Canada Opportunities Agency, Bloom Burton & Co. Inc., Defense Threat Reduction Agency, FUJIFILM Toyama Chemical Co., Ltd., Invest Nova Scotia, Long Zone Holdings Inc., National Research Council of Canada's Industrial Research Assistance Program, Nova Scotia Innovation, NSBI Venture Capital, The Lind Partners, LLC

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.05
Market Cap (mm)
5.5
Open
 0.05
Shares Out. (mm)
121.3
Previous Close
 0.05
Float %
88.1%
Change on Day
(0.01)
Shares Sold Short (mm)
-
Change % on Day
(10.0)%
Dividend Yield %
-
Day High/Low
 0.05/ 0.05
Diluted EPS Excl. Extra Items
(0.07)
52 wk High/Low
 0.08/ 0.03
P/Diluted EPS Before Extra
NM
Volume (mm)
0.19
Avg 3M Dly Vlm (mm)
0.35
Beta 5Y
1.05


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
TSX:APLI - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-29-2022
-
Private Placement
Target
Appili Therapeutics Inc. (TSX:APLI)
Defense Threat Reduction Agency

10.00
May-17-2022
May-26-2022
Public Offering
Target
Appili Therapeutics Inc. (TSX:APLI)


3.52
May-5-2022
-
Shelf Registration
Target
Appili Therapeutics Inc. (TSX:APLI)


11.69
Mar-29-2022
-
Private Placement
Target
Appili Therapeutics Inc. (TSX:APLI)
Long Zone Holdings Inc.

3.28
Oct-6-2021
Oct-14-2021
Public Offering
Target
Appili Therapeutics Inc. (TSX:APLI)


5.66
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-27-2023
Shareholder/Analyst Calls
Appili Therapeutics Inc. - Shareholder/Analyst Call
Sep-27-2023
Annual General Meeting
Appili Therapeutics Inc., Annual General Meeting, Sep 27, 2023
Sep-25-2023
Product-Related Announcements
Appili Therapeutics Announces U.S. FDA Approval of Likmez (ATI-1501) Metronidazole Oral Suspension
May-08-2023
Client Announcements
Appili Therapeutics Inc. Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy
Apr-26-2023
Company Conference Presentations
Appili Therapeutics Inc. Presents at 2023 Bloom Burton & Co. Healthcare Investor Conference, Apr-26-2023 03:30 PM


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
Private Placement Advisors
Bloom Burton Securities Inc., Haywood Securities (USA) Inc., Industrial Alliance Securities Inc., Research Capital Corporation, Richardson GMP Limited, Investment Banking Arm
Public Offering Advisors
Dentons Canada LLP, PricewaterhouseCoopers LLP, PricewaterhouseCoopers LLP, Canada, Troutman Pepper Hamilton Sanders LLP


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Zacks Small-Cap Research
Bautz, David
10:01 AM
APLI
APLIF: FDA Approves LIKMEZ  (ATI-1501)
Reports
7
GlobalData

Sep 15, 2023 03:34 AM
APLI
Appili Therapeutics Inc (APLI.TSE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
40
GlobalData

Sep 13, 2023 04:00 AM
APLI
Appili Therapeutics Inc (APLI.TSE) - Financial Analysis Review
Reports
148
GlobalData

Aug 29, 2023 01:52 AM
APLI
Appili Therapeutics Inc (APLI.TSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
47
Zacks Small-Cap Research
Bautz, David
Jul 17, 2023 11:00 AM
APLI
APLIF: Executes Initial Contract with USAFA for Development of ATI-1701
Reports
7
Zacks Small-Cap Research
Bautz, David
Jul 17, 2023 06:00 AM
APLI
T.APL: Executes Initial Contract with USAFA for Development of ATI-1701
Reports
7
GlobalData

Jun 14, 2023 05:02 AM
APLI
Appili Therapeutics Inc (APLI.TSE) - Financial Analysis Review
Reports
147
GlobalData

Jun 09, 2023 06:30 AM
APLI
Appili Therapeutics Inc (APLI.TSE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
43
Wright Investors' Service Inc.

May 24, 2023 01:41 AM
APLI
Flow of Funds Report for Appili Therapeutics Inc - prepared by Wright Investors Service
Notes
69
GlobalData

May 17, 2023 05:36 AM
APLI
Appili Therapeutics Inc (APLI.TSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
47


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Bloom Burton Investment Group Inc.

14,358,611

11.84

0.7

Aug-18-2023


Cilla Jr., M.B.A., Pharmd, Donald D.

75,000

0.06

0.0

Aug-18-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Cilla Jr., M.B.A., Pharmd, Donald D.
75,000
75,000

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
ATI-1501 (Future), ATI-1503, ATI-1701 (Future), ATI-1801 (Future), ATI-2307, Favipiravir (Future)


Upcoming Events
Date/Time
Type
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Sep-27-2023
Appili Therapeutics Inc. (TSX:APLI)
SEDAR
News Releases
134 KB
Sep-27-2023
Appili Therapeutics Inc. (TSX:APLI)
SEDAR
News Releases
136 KB
Sep-27-2023
Appili Therapeutics Inc. (TSX:APLI)
SEDAR
Material Change Report
190 KB
Sep-27-2023
Appili Therapeutics Inc. (TSX:APLI)
SEDAR
Management Proxy Materials
91 KB
Sep-25-2023
Appili Therapeutics Inc. (TSX:APLI)
SEDAR
News Releases
141 KB
Sep-25-2023
Appili Therapeutics Inc. (TSX:APLI)
SEDAR
News Releases
141 KB
Sep-25-2023
Appili Therapeutics Inc. (TSX:APLI)
SEDAR
News Releases
141 KB
Aug-22-2023
Appili Therapeutics Inc. (TSX:APLI)
SEDAR
Management Proxy Materials
70 KB
Aug-22-2023
Appili Therapeutics Inc. (TSX:APLI)
SEDAR
Management Proxy Materials
793 KB
Aug-22-2023
Appili Therapeutics Inc. (TSX:APLI)
SEDAR
Management Proxy Materials
644 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Cilla Jr., M.B.A., Pharmd, Donald D. (CEO, President & Director)
May-08-2023
Class A Common Shares
75,000
3,086
Open Market Acquisition
New
Multiple
K2 & Associates Investment Management Inc.
Nov-29-2021
Class A Common Shares
(237,200)
(38,594)
Open Market Disposition
(4.28)
Multiple
K2 & Associates Investment Management Inc.
Jul-08-2021
Class A Common Shares
500
361
Open Market Acquisition
0.01
Exchange Announcement
K2 & Associates Investment Management Inc.
Jun-30-2021
Class A Common Shares
1,000
710
Open Market Acquisition
0.02
Exchange Announcement
K2 & Associates Investment Management Inc.
Jun-21-2021
Class A Common Shares
36,500
28,918
Open Market Acquisition
0.66
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Balboni, Armand 
Chairman of the Board
(416) 640-7574
-
abalboni@bloomburton.com
Cilla, Donald D.
CEO, President & Director
902-442-4655 
-

Matkovits, Theresa 
Lead Independent Director
902-442-4655 
-

Stenzler, Rochelle E.
Independent Director
902-442-4655 
-

Bloom, Brian Matthew
Director
(416) 640-7580
-
bbloom@bloomburton.com
Froehlich, Juergen 
Independent Director
902-442-4655 
-
juergen.froehlich@enbiotix.com
Marusic, Lidija 
Board Observer
902-424-8670 x1505
-
lmarusic@innovacorp.ca
Narayan, Sridhar 
Member of Scientific Advisory Board
902-442-4655 
-

Shinabarger, Dean L.
Member of Advisory Board
902-442-4655 
-
dlshinabarger@micromyx.com
Silver, Lynn L.
Member of Advisory Board
902-442-4655 
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Cilla, Donald D.
CEO, President & Director
902-442-4655 
-

Howling, Kenneth G.
Chief Financial Officer
902-442-4655 
-
khowling@appilitherapeutics.com
Nabors, Gary S.
Chief Development Officer
902-442-4655 
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
